Boswellia serrata preserves intestinal epithelial barrier from oxidative and inflammatory damage

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Catanzaro, Daniela ^a   Rancan, Serena ^a   Orso, Genny ^b   Dall'acqua, Stefano ^a   Brun, Paola ^a   Giron, Maria Cecilia ^a   Carrara, Maria ^a   Castagliuolo, Ignazio ^a   Ragazzi, Eugenio ^a   Caparrotta, Laura ^a   Montopoli, Monica ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL 11 KETO BETA BOSWELLIC ACID; ANTIINFLAMMATORY AGENT; BOSWELLIA SERRATA EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OCCLUDIN; PROTEIN ZO1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ACETYL-11-KETOBOSWELLIC ACID; ANTIOXIDANT; HYDROGEN PEROXIDE; PLANT EXTRACT; TIGHT JUNCTION PROTEIN; TRITERPENE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CACO 2 CELL LINE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG DETERMINATION; DRUG MECHANISM; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTESTINE CELL; INTESTINE EPITHELIUM; OXIDATIVE STRESS; PERMEABILITY BARRIER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; BOSWELLIA; CACO-2 CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; HUMAN; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

ANTIOXIDANTS; BOSWELLIA; CACO-2 CELLS; CELL SURVIVAL; EPITHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; NF-KAPPA B; PLANT EXTRACTS; TIGHT JUNCTION PROTEINS; TRITERPENES;

EID: 84954176344     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125375     Document Type: Article

References (51)

1. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862. PMID: 11241255
2. Mudter J. What's new about inflammatory bowel diseases in 2011. World J Gastroenterol 2011;17:3177. doi: 10.3748/wjg.v17.i27.3177 PMID: 21912464
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434. PMID: 17653185
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-2078. doi: 10.1056/NEJMra0804647 PMID: 19923578
5. Peloquin JM, Nguyen DD. Themicrobiotaand inflammatory bowel disease: insights from animal models. Anaerobe. 2013;24:102-106. doi: 10.1016/j.anaerobe.2013.04.006 PMID: 23603043
6. Yapali S, Hamzaoglu HO. Anti-TNF treatment in inflammatory bowel disease. Annals Gastroenterol. 2007;20:48-53.
7. Guidi L, Pugliese D, Armuzzi A. Update on the management of inflammatory bowel disease: specific role of dalimumab. Clin Exp Gastroenterol. 2011;4:163-172. doi: 10.2147/CEG. S14558 PMID: 21904462
8. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC et al. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:854-863. doi: 10.1111/apt. 12464 PMID: 23981095
9. Fei K, Praveen KY, Liu ZJ. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol. 2012;18:3-10. doi: 10.4103/1319-3767.91726 PMID: 22249085
10. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med. 2012;237:474-480. doi: 10.1258/ebm.2011. 011358 PMID: 22442342
11. Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol. 2012;590:1035-1044. doi: 10.1113/jphysiol.2011.224568 PMID: 22219336
12. Moussaieffa A, Mechoulamb R. Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol. 2009;61:1281-1293. doi: 10.1211/jpp/61.10. 0003 PMID: 19814859
13. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73:255-261. doi: 10.4103/0250-474X.93507 PMID: 22457547
14. Gupta I, Parihar A, Malhotra P, Gupta S, Lüdtke R, Safayhi H et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2011;67:391-395.
15. Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E etal. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007;22:1445-1451. PMID: 17764013
16. Huang MT, Badmaev V, Ding Y, Liu Y, Xie JG, HoCT. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors. 2000;13:225-230. PMID: 11237186
17. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011;50:349-369. doi: 10.2165/11586800-000000000-00000 PMID: 21553931
18. Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr MedChem. 2006;13:3359-3369. PMID: 17168710
19. Anthoni C, Laukoetter MG, Rijcken E, Vowinkel T, Mennigen R, Müller S et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1131-G1137. PMID: 16423918
20. Ammon HP. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine. 2010;17:862-867. doi: 10.1016/j.phymed.2010.03.003 PMID: 20696559
21. Cao M, Wang P, Sun C, He W, Wang F. Amelioration of IFN-γ and TNF-αinduced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One. 2013;8(5):e61944. doi: 10.1371/journal.pone.0061944 PMID: 23671580
22. Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin andcisplatin oroxaliplatin in human ovarian carcinoma cells. Cell Prolif. 2009;42:195-206. doi: 10.1111/j.1365-2184.2009.00585.x PMID: 19236381
23. Perli E, Giordano C, Tuppen HA, Montopoli M, Montanari A, Orlandi M et al. Isoleucyl-tRNAsynthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA (Ile) mutation causing hypertrophic cardiomyopathy. HumMol Genet. 2012;21:85-100. doi: 10.1093/hmg/ddr440 PMID: 21945886
24. Rotoli BM, Bussolati O, Dall Asta V, Orlandini G, Gatti R, Gazzola GC. Secretin increases the paracellular permeability of CAPAN-1 pancreatic duct cells. Cell Physiol Biochem. 2000;10:13-25. PMID: 10844394
25. Balimane PV, Chong S. Cell culture-based models for intestinal permeability: A critique. Drug Discovery Today. 2005;10:335-343. PMID: 15749282
26. Konishi Y, Hagiwara K, Shimizu M. Transepithelial transport of fluorescein in Caco-2cell monolayers and use of such transport in in vitro evaluation of phenolic acid availability. Biosci Biotechnol Biochem. 2002;66:2449-2457. PMID: 12506986
27. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2013;70:631-659. doi: 10.1007/s00018-012-1070-x PMID: 22782113
28. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med 2008;263:591-596. doi: 10.1111/j.1365-2796.2008.01953.x PMID: 18479258
29. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J et al. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Rad Biol Med. 2002;33:311-322. PMID: 12126753
30. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol. 2005;11:2371-2384. PMID: 15832404
31. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362-381. doi: 10.1002/ibd.21403 PMID: 20725949
32. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol. 2013;4:280. doi: 10.3389/fimmu.2013.00280 PMID: 24062746
33. Ping W, Hao C, Yuan G, Ai-Ping B. Advances in treatment of ulcerative colitis with herbs: from bench to bedside. World J Gastroenterol. 2014;20:14099-14104. doi: 10.3748/wjg.v20.i39.14099 PMID: 25339799
34. Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol. 2013;19:5738-5749. doi: 10.3748/wjg.v19.i34.5738 PMID: 24039370
35. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J ChromatogrA. 2006;1112:255-262. PMID: 16364338
36. Peterson MD, Bement WM, Mooseker MS. An in vitro model for the analysis of intestinal brush border assembly. I. Ultrastructural analysis of cell contact-induced brush border assembly in Caco-2BBe cells. J Cell Sci. 1993;105:445-460. PMID: 8408276
37. Fleet JC, Wang L, Vitek O, Craig BA, Edenberg HJ. Gene expression profiling of Caco-2 BBe cells suggests a role for specific signaling pathways during intestinal differentiation. Physiol Genomics. 2003;13:57-68. PMID: 12644633
38. Mariadason JM, Arango D, Corner GA, Aranes MJ, Hotchkiss KA, Yang W et al. A gene expression profile that defines colon cell maturation in vitro. Cancer Res. 2002;62:4791-4804. PMID: 12183439
39. Wang F, Schwarz BT, Graham W V, Wang Y, Su L, Clayburgh DR etal. IFN-gamma-inducedTNFR2 expression is required forTNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006;131:1153-1163. PMID: 17030185
40. Liu H, Wang P, Cao M, Li M, Wang F. Protective roleof oligomycin against intestinal epithelial barrier dysfunction caused by IFN-γ and TNF-α. Cell Physiol Biochem. 2012;29:799-808. doi: 10.1159/000188076 PMID: 22613980
41. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809. doi: 10.1038/nri2653 PMID: 19855405
42. Shin K, Fogg VC, Margolis B. Tight junctions and cell polarity. Ann Rev Cell Dev Biol. 2006;22:207-235. PMID: 16771626
43. Harhaj S, Antonetti DA. Regulation of tight junctions and loss of barrierfunction in pathophysiology. Int J Biochem Cell Biol. 2004;36:1206-1237. PMID: 15109567
44. Li Q, Zhang Q, Wang M, Zhao S, Ma J, Luo N et al. Interferon-gamma and tumor necrosis factor-alpha disrupt epithelial barrierfunction by altering lipid composition in membrane microdomains of tight junction. Clin Immunol. 2008;126:67-80. PMID: 17964857
45. John LJ, Fromm M, Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal. 2011;15:1255-1270. doi: 10.1089/ars.2011.3892 PMID: 21294654
46. Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA et al. TNF-α-induced-induced increase in intestinal epithelial tight junction permeability requires NF-kB activation. Am J Physiol Gastrointest Liver Physiol. 2004;286:G367-G376. PMID: 14766535
47. Beutheu YS, Belmonte L, Galas L, Boukhettala N, Bôle-Feysot C, Déchelotte P et al. Methotrexate Modulates Tight Junctions Through NF-[kappa]B, MEK, and JNK Pathways. J Ped Gastroenterol Nutr. 2012;54:463-470. doi: 10.1097/MPG.0b013e318247240d PMID: 22197938
48. Hartmann RM, Fillmann HS, Martins MI, Meurer L, Marroni NP. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res. 2014;28:1392-1398. doi: 10.1002/ptr.5142 PMID: 24619538
49. Blau S, Rubinstein A, Bass P, Singaram C, Kohen R. Differences in the reducing power along the ratGI tract: lower antioxidant capacity of the colon. MolCell Biochem. 1999;194:185-191. PMID: 10391139
50. Kiela PR, Midura AJ, Kuscuoglu N, Jolad SD, Sólyom AM, Besselsen DG, et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G798-G808. PMID: 15539433
51. Florean C, Diederich M. Redox regulation: natural compound as regulators of inflammation signaling. Biochem Pharmacol. 2012;84:1223-1224. doi: 10.1016/j.bcp. 2012.07.001 PMID: 22796567